LogicBio Therapeutics, Inc. (LOGC)
| Market Cap | 56.03M |
| Revenue (ttm) | 3.93M |
| Net Income (ttm) | -37.87M |
| Shares Out | 32.96M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 59,341 |
| Open | 1.78 |
| Previous Close | 1.76 |
| Day's Range | 1.69 - 1.78 |
| 52-Week Range | 1.69 - 9.74 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 14.20 (+735.3%) |
| Earnings Date | n/a |
About LOGC
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene thera...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LOGC stock is "Buy." The 12-month stock price forecast is 14.20, which is an increase of 735.29% from the latest price.
News
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Cher...
LogicBio Therapeutics Provides Business Updates
LEXINGTON, Mass., Dec. 22, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial ...
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
LEXINGTON, Mass., Nov. 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter ended Septem...
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Nov. 11, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic...
Will LogicBio Therapeutics (LOGC) Report Negative Q3 Earnings? What You Should Know
LogicBio Therapeutics (LOGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes...
LEXINGTON, Mass., Oct. 21, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today is slated to present new preclinical data on its GeneRide™ pla...
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
LEXINGTON, Mass., Oct. 18, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever ...
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress...
LEXINGTON, Mass., Oct. 12, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare a...
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
LEXINGTON, Mass., Sept. 24, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare ...
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
LEXINGTON, Mass., Sept. 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare ...
LogicBio Therapeutics (LOGC) Reports Q2 Loss, Lags Revenue Estimates
LogicBio Therapeutics (LOGC) delivered earnings and revenue surprises of -32.00% and -83.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LogicBio Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones
LEXINGTON, Mass., Aug. 9, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatm...
LEXINGTON, Mass., June 2, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appoi...
LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...
LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing pl...
LogicBio Therapeutics Strengthens Management Team with Key Appointments
LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...
LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
LEXINGTON, Mass., May 4, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...
LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalo...
LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...
LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates
CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to develop, manufacture and commercialize gene therapy cand...
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery ...
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Announces Rare Disease Collaboration with LogicBio and Licenses on Gene Editing & Delivery, Worldwide and in Greater China
LogicBio Therapeutics Announces Clinical and Corporate Updates
LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...
LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo
LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to a...
LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit
LEXINGTON, Mass., March 30, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...
LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
LEXINGTON, Mass., March 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing...